ARID1A and papillary serous cystadenocarcinoma: A retrospective study conducted by Xiao et al. examining molecular alterations found loss of BAF250a expression in about 20% of TE, and a similar pattern of expression in AE (38.5%) and CCC (57.7%) in comparison to papillary serous carcinoma [33].